{"created":"2023-05-15T15:00:54.542733+00:00","id":82621,"links":{},"metadata":{"_buckets":{"deposit":"201537ac-38f5-45c2-8622-694811db69d5"},"_deposit":{"created_by":1,"id":"82621","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"82621"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00082621","sets":["7"]},"author_link":["944232","944231"],"item_10004_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2021-03","bibliographicIssueDateType":"Issued"},"bibliographicPageEnd":"16","bibliographicPageStart":"16","bibliographic_titles":[{"bibliographic_title":"QST Takasaki Annual Report 2019 "}]}]},"item_10004_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Positron emission tomography (PET) with amino acid analogs has great impacts on the treatment of cancer by diagnosis, staging, and monitoring. Among them, 3-18F-fluoro-α-methyl-L-tyrosine (18F-FAMT) has been routinely used for tumor diagnosis in Gunma University Hospital. The specific accumulation of 18F-FAMT in malignant tumors is exclusively promoted by L-type amino acid transporter 1 (LAT1), the expression of which is highly upregulated in many types of cancers. However, a major drawback of 18F-FAMT PET is the relatively high frequency of false-negative results because of its low tumor accumulation level. These clinical findings have prompted the further development of 18F-FAMT analogs with higher tumor accumulation and improved pharmacokinetics. In this study, we prepared 18F-FAMP regioisomers (2-, 3-, or 4-18F-FAMP) and stereoisomers (L- or D-form), and we comprehensively evaluated their potential as tumor-imaging agents. ","subitem_description_type":"Abstract"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Yasuhiro, Oshima"}],"nameIdentifiers":[{"nameIdentifier":"944231","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Yasuhiro, Oshima","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"944232","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Novel 18F-labeled α-methyl-phenylalanine derivative with high tumor accumulation and ideal pharmacokinetics for tumor-specific imaging","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Novel 18F-labeled α-methyl-phenylalanine derivative with high tumor accumulation and ideal pharmacokinetics for tumor-specific imaging"}]},"item_type_id":"10004","owner":"1","path":["7"],"pubdate":{"attribute_name":"公開日","attribute_value":"2021-04-05"},"publish_date":"2021-04-05","publish_status":"0","recid":"82621","relation_version_is_last":true,"title":["Novel 18F-labeled α-methyl-phenylalanine derivative with high tumor accumulation and ideal pharmacokinetics for tumor-specific imaging"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T20:16:43.478395+00:00"}